Payment takes place through promissory notes which are set off in their entirety against newly issued shares in WntResearch, the company states.

If the transaction is approved, it will mean that WntResearch’s current business will cease and be replaced by OPSY’s innovative solution in the insurance medical field.

“We are very pleased to propose this reverse acquisition to our shareholders. If the transaction is approved, it will mean that WntResearch’s current business will cease and be replaced by OPSY’s innovative solution in the insurance medical field. Our patents and our documentation will remain in the company’s possession, which means that it is still possible to find an external taker for these assets, although of course the probability decreases as we are no longer actively working on this. The reverse acquisition of OPSY instead gives our owners a new opportunity for future upside. OPSY has very quickly gained market share in the insurance medical field and has good opportunities to expand its operations outside of Sweden’s borders in the future,” says Per Norlén, CEO of WntResearch.

Related article

Navigating the Financial Landscape: Reverse Merger

When InDex Pharmaceuticals announced earlier this year that it would discontinue all development of the company’s drug candidate, Flerie Invest saw an opportunity to become listed and offer new shareholders access to and liquidity in biotech companies while retaining its long-term, active investment strategy.

The agreement is conditional, among other things, on the extraordinary general meeting on 7 March 2025 approving the transaction and deciding on a new issue of shares to the sellers, whereby payment must be made by set-off.

The shareholders Lars-Erik Forsgårdh, Kjell Stenberg and Christian Haarlem, who together, directly and indirectly, hold approximately 6.6 percent of the total number of shares and votes in WntResearch, have undertaken to vote for the transaction and related decisions at the extraordinary general meeting.

Opsy Holding AB

The commercial outcome of the transaction is that WntResearch will continue OPSY’s business as a listed company on the Spotlight Stock Market, following the completion of the approval process with Spotlight. The company also intends to propose a name change to Opsy Holding AB.

“We are very pleased to take this important step to secure OPSY’s long-term growth and strengthen our position as a leading player in digital solutions for automation of claims settlement processes. The acquisition of OPSY represents a unique opportunity to take our platform and services to the next level and reach more customers via a listed environment. Together with WntResearch’s shareholders, we look forward to continuing to develop the industry through innovation and efficiency, while creating value for all stakeholders,” says Arne Thor, founder and managing director and board member of OPSY.